Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Seroprevalence of SARS-CoV-2 in slums and non-slums of Mumbai, India, during June 29-July 19, 2020

Anup Malani, Daksha Shah, Gagandeep Kang, Gayatri Nair Lobo, Jayanthi Shastri, Manoj Mohanan, Rajesh Jain, Sachee Agrawal, Sandeep Juneja, Sofia Imad, Ullas Kolthur
doi: https://doi.org/10.1101/2020.08.27.20182741
Anup Malani
1Medical School and Law School, University of Chicago, Chicago, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daksha Shah
2Brahinmumbai Municipal Corporation, Mumbai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gagandeep Kang
3Department of Gastrointestinal Sciences, Vellore Christian Medical College, Vellore, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gayatri Nair Lobo
4A.T.E. Chandra Foundation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jayanthi Shastri
5Kasturba Hospital, Mumbai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manoj Mohanan
6Sanford School of Public Policy, Duke University, Durham, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rajesh Jain
7Clinical Development Services Agency
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sachee Agrawal
8T.N. Medical College & B.Y.L. Nair Ch. Hospital, Mumbai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandeep Juneja
9School of Technology and Computer Science, Tata Institute for Fundamental Research, Mumbai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sofia Imad
10IDFC Institute, Mumbai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ullas Kolthur
11Department of Biological Sciences, Tata Institute for Fundamental Research, Mumbai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ullas@tifr.res.in
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Objective Estimate seroprevalence in representative samples from slum and non-slum communities in Mumbai, India, a mega-city in a low or middle-income country and test if prevalence is different in slums.

Design After geographically-spaced community sampling of households, one individual per household was tested for IgG antibodies to SARS-CoV-2 N-protein in a two-week interval.

Setting Slum and non-slum communities in three wards, one each from the three main zones of Mumbai.

Participants Individuals over age 12 who consent to and have no contraindications to venipuncture were eligible. 6,904 participants (4,202 from slums and 2,702 from non-slums) were tested.

Main outcome measures The primary outcomes were the positive test rate for IgG antibodies to the SARS-CoV-2 N-protein by demographic group (age and gender) and location (slums and non-slums). The secondary outcome is seroprevalence at slum and non-slum levels. Sera was tested via chemiluminescence (CLIA) using Abbott Diagnostics ArchitectTM N-protein based test. Seroprevalence was calculated using weights to match the population distribution by age and gender and accounting for imperfect sensitivity and specificity of the test.

Results The positive test rate was 54.1% (95% CI: 52.7 to 55.6) and 16.1% (95% CI: 14.9 to 17.4) in slums and non-slums, respectively, a difference of 38 percentage points (P < 0.001). Accounting for imperfect accuracy of tests (e.g., sensitivity, 0.90; specificity 1.00), seroprevalence was as high as 58.4% (95% CI: 56.8 to 59.9) and 17.3% (95% CI: 16 to 18.7) in slums and non-slums, respectively.

Conclusions The high seroprevalence in slums implies a moderate infection fatality rate. The stark difference in seroprevalence across slums and non-slums has implications for the efficacy of social distancing, the level of herd immunity, and equity. It underlines the importance of geographic specificity and urban structure in modeling SARS-CoV-2.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The study was sponsored by Action Covid19 Team, A.T.E. Chandra Foundation, and Godrej Industries.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the IRBs of TIFR (TIFR/IHEC/2020-1), Kasturba Hospital (IRB 20/2020), THSTI (EC/NEW/INST/2019/275), Duke University (Protocol:2020-0575) and University of Chicago (IRB20-1144).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data availability remains under consideration.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted September 01, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Seroprevalence of SARS-CoV-2 in slums and non-slums of Mumbai, India, during June 29-July 19, 2020
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Seroprevalence of SARS-CoV-2 in slums and non-slums of Mumbai, India, during June 29-July 19, 2020
Anup Malani, Daksha Shah, Gagandeep Kang, Gayatri Nair Lobo, Jayanthi Shastri, Manoj Mohanan, Rajesh Jain, Sachee Agrawal, Sandeep Juneja, Sofia Imad, Ullas Kolthur
medRxiv 2020.08.27.20182741; doi: https://doi.org/10.1101/2020.08.27.20182741
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Seroprevalence of SARS-CoV-2 in slums and non-slums of Mumbai, India, during June 29-July 19, 2020
Anup Malani, Daksha Shah, Gagandeep Kang, Gayatri Nair Lobo, Jayanthi Shastri, Manoj Mohanan, Rajesh Jain, Sachee Agrawal, Sandeep Juneja, Sofia Imad, Ullas Kolthur
medRxiv 2020.08.27.20182741; doi: https://doi.org/10.1101/2020.08.27.20182741

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (166)
  • Anesthesia (49)
  • Cardiovascular Medicine (448)
  • Dentistry and Oral Medicine (80)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (188)
  • Epidemiology (5199)
  • Forensic Medicine (3)
  • Gastroenterology (193)
  • Genetic and Genomic Medicine (746)
  • Geriatric Medicine (76)
  • Health Economics (211)
  • Health Informatics (690)
  • Health Policy (350)
  • Health Systems and Quality Improvement (221)
  • Hematology (98)
  • HIV/AIDS (161)
  • Infectious Diseases (except HIV/AIDS) (5793)
  • Intensive Care and Critical Care Medicine (355)
  • Medical Education (101)
  • Medical Ethics (25)
  • Nephrology (80)
  • Neurology (754)
  • Nursing (43)
  • Nutrition (129)
  • Obstetrics and Gynecology (141)
  • Occupational and Environmental Health (230)
  • Oncology (473)
  • Ophthalmology (149)
  • Orthopedics (38)
  • Otolaryngology (93)
  • Pain Medicine (39)
  • Palliative Medicine (19)
  • Pathology (138)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (135)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (851)
  • Public and Global Health (1986)
  • Radiology and Imaging (342)
  • Rehabilitation Medicine and Physical Therapy (154)
  • Respiratory Medicine (282)
  • Rheumatology (93)
  • Sexual and Reproductive Health (72)
  • Sports Medicine (74)
  • Surgery (107)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)